Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

5.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

77.8K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.8K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

5.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Current chemical approaches in combating neuroinflammation in Alzheimer's disease (AD).

Frontiers in aging neuroscience·2025
Same author

Radical-induced lipid oxidation produces a torrent of leukotriene-like agonists in severe asthma.

The Journal of allergy and clinical immunology·2025
Same author

Transient receptor potential vanilloid type 4 channels mediate bladder cancer cell proliferation, migration, and chemoresistance.

The Journal of pharmacology and experimental therapeutics·2025
Same author

Endothelial metabolic zonation in the vascular network: a spatiotemporal blueprint for angiogenesis.

American journal of physiology. Heart and circulatory physiology·2025
Same author

Leukotrienes: Bridging the Inflammatory Gap in Asthma and Inflammatory Bowel Diseases (IBD).

Comprehensive Physiology·2025
Same author

Microbiota in Gut-Heart Axis: Metabolites and Mechanisms in Cardiovascular Disease.

Comprehensive Physiology·2025

Related Experiment Video

Updated: Jun 17, 2025

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay
09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

886

A TRP to Pathological Angiogenesis and Vascular Normalization.

Venkatesh Katari1, Kesha Dalal1, Ravi K Adapala1

  • 1Department of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.

Comprehensive Physiology
|August 7, 2024
PubMed
Summary
This summary is machine-generated.

Targeting calcium channels, specifically TRPV4, offers a novel approach to normalize pathological angiogenesis. This strategy aims to overcome limitations of current anti-VEGF therapies for cancer and eye diseases.

More Related Videos

Translating Ribosome Affinity Purification TRAP for RNA Isolation from Endothelial Cells In Vivo
08:53

Translating Ribosome Affinity Purification TRAP for RNA Isolation from Endothelial Cells In Vivo

Published on: May 25, 2019

11.8K
In Vitro Model of Coronary Angiogenesis
08:03

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

7.7K

Related Experiment Videos

Last Updated: Jun 17, 2025

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay
09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

886
Translating Ribosome Affinity Purification TRAP for RNA Isolation from Endothelial Cells In Vivo
08:53

Translating Ribosome Affinity Purification TRAP for RNA Isolation from Endothelial Cells In Vivo

Published on: May 25, 2019

11.8K
In Vitro Model of Coronary Angiogenesis
08:03

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

7.7K

Area of Science:

  • Physiology
  • Molecular Biology
  • Pathology

Background:

  • Uncontrolled angiogenesis drives diseases like cancer and AMD.
  • Current anti-VEGF therapies face resistance and adverse effects.
  • Novel strategies are needed to target pathological angiogenesis.

Purpose of the Study:

  • To review the role of transient receptor potential (TRP) channels, focusing on TRPV4, in pathological angiogenesis.
  • To explore TRPV4's downstream signaling pathways and its modulation by the tumor microenvironment.
  • To highlight endothelial TRPV4 as a potential therapeutic target for vascular normalization.

Main Methods:

  • Literature review on calcium channels and angiogenesis.
  • Focus on TRPV4's role in endothelial cells.
  • Analysis of tumor microenvironment's impact on TRPV4 signaling.

Main Results:

  • Calcium channels, particularly TRPV4, are key regulators of angiogenesis.
  • TRPV4 activity is modulated by tumor microenvironment via Rho/YAP/VEGFR2 pathways.
  • Endothelial TRPV4 influences pathological angiogenesis and vascular normalization.

Conclusions:

  • Endothelial TRPV4 presents a promising therapeutic target for vascular normalization.
  • TRPV4 modulation offers an alternative to anti-VEGF strategies.
  • Targeting TRPV4 could improve treatments for cancer and neovascular ocular diseases.